Biologic therapies for chronic obstructive pulmonary disease.
Maria Gabriella MateraLuigino CalzettaMario CazzolaJosuel OraRogliani PaolaPublished in: Expert opinion on biological therapy (2022)
No mAb directed against cytokines or chemokines has shown any therapeutic impact in COPD patients, apart from mAbs targeting the IL-5 pathway that appear to have statistically significant, albeit weak, effect in patients with eosinophilic COPD. This may reflect the complexity of COPD, in which no single cytokine or chemokine has a dominant role. Because the umbrella term COPD encompasses several endotypes with diverse underlying processes, mAbs targeting specific cytokines or chemokines should most likely be evaluated in limited and focused populations.
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- cancer therapy
- peritoneal dialysis
- prognostic factors
- cystic fibrosis
- air pollution
- randomized controlled trial
- preterm infants
- systematic review
- patient reported
- chronic rhinosinusitis
- meta analyses